News

Oct 27, 2024

Episurf Medical Third Quarter 2024 Earnings: kr0.024 loss per share (vs kr0.078 loss in 3Q 2023) - Simply Wall St News

All figures shown in the chart above are for the trailing 12 month (TTM) period Looking ahead, revenue is forecast to grow 70% p.a. on average during the next 3 years, compared to a 18% growth

All figures shown in the chart above are for the trailing 12 month (TTM) period

Looking ahead, revenue is forecast to grow 70% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Medical Equipment industry in Sweden.

Performance of the Swedish Medical Equipment industry.

The company's shares are up 6.6% from a week ago.

You should learn about the 6 warning signs we've spotted with Episurf Medical (including 3 which are concerning).

Discover if Episurf Medical might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

A medical device company, designs and manufactures implants and surgical instruments in Germany, Sweden, rest of Europe, the United States, and internationally.

Medium-low with adequate balance sheet.